与BACE1抑制剂相关的安全问题 - 过去,现在和未来
Aniketh Naidu1, Bret Silverglate1, Mary Silverglate2
1Department of Psychiatry and Behavioral Neuroscience, Division of Geriatrics, Saint Louis University School of Medicine, St. Louis, MO, USA.
Expert opinion on drug safety
|February 14, 2025
概括
贝塔位粉样蛋白前体蛋白分裂酶1 (BACE1) 抑制剂对阿尔茨海默氏症 (AD) 有希望. 然而,广泛的BACE1表达会导致不良影响,需要中枢神经系统特异性抑制剂.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块.
- BACE1抑制剂旨在减少Aβ的产生,这是AD的一个关键病理标志.
- 以前的BACE1抑制剂在临床试验中因疗效和不良反应而面临挑战.
研究的目的:
- 对阿尔茨海默病的BACE1抑制剂进行随机对照试验 (RCT) 的审查.
- 分析BACE1抑制剂的疗效和安全性.
- 讨论BACE1的脑外表达对治疗结果的影响.
主要方法:
- 一个叙事文学的评论.
- 在PubMed和Web of Science数据库中进行的搜索.
- 包括2010年至2024年间发表的研究.
主要成果:
- 对BACE1抑制剂如atabecestat,verubecestat和lanabecestat的临床试验表明有效性有限.
- 观察到显著的不良影响,包括焦虑,抑郁症状和肝毒性.
- 这些不良影响与BACE1在中枢神经系统之外的广泛表达有关.
结论:
- 开发特定于中枢神经系统的BACE1抑制剂对于减轻不良影响至关重要.
- 优化药物设计和探索替代治疗点对于未来的AD治疗策略至关重要.
- 进一步的研究可能会探索其他疾病的BACE1抑制剂,如前列腺癌和胰岛素抵抗.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
457
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
457
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
703
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
703
01:20Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
01:25Antihypertensive Drugs: Direct Renin Inhibitors
474
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474